NCT06001567 is a Phase 2 clinical trial of Avatrombopag in Thrombocytopenia, sponsored by Second Affiliated Hospital of Guangzhou Medical University.

Who is sponsoring NCT06001567?

NCT06001567 is sponsored by Second Affiliated Hospital of Guangzhou Medical University.

What drugs are being tested in NCT06001567?

Interventions in NCT06001567: Avatrombopag.

What condition does NCT06001567 study?

NCT06001567 studies Thrombocytopenia, Hepatocellular Carcinoma.

Is NCT06001567 still recruiting?

NCT06001567 is currently status unknown. Last updated 14 September 2023.

Last reviewed 2023-09-14 · How we verify

NCT06001567

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC

Status unknown Phase 2 Last updated 14 September 2023

What this trial tests

Phase 2 trial testing Avatrombopag in Thrombocytopenia in 30 participants. Status unknown.

Timeline

14 August 2023

Primary endpoint
13 August 2024

13 August 2024

Quick facts

Lead sponsor	Second Affiliated Hospital of Guangzhou Medical University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	14 August 2023
Primary completion	13 August 2024
Estimated completion	13 August 2024
Sites	1 location across China

Drugs / interventions tested

Avatrombopag (AVATROMBOPAG) — full drug profile →

Conditions studied

Thrombocytopenia — all drugs for Thrombocytopenia →
Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Who can join

18 and older, any sex, with Thrombocytopenia or Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is conducted to evaluate the efficacy of avatrombopag for thrombocytopenia in patients with hepatocellular carcinoma (HCC) who intend to undergo transarterial chemoembolization (TACE) and/or hepatic arterial infusion chemotherapy (HAIC).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Immunological Landscape and Molecular Therapeutic Targets of the Tumor Microenvironment in Hepatocellular Carcinoma.
Zarlashat Y, Ghaffar A, Guerra F, Picca A. · · 2025 · cited 3× · PMID 40869156 · DOI 10.3390/ijms26167836

Verify or expand the search:

Other trials of Avatrombopag

Trials testing the same drug.

NCT07051915 — The Holistic Study · Phase 3 · not yet recruiting
NCT06254287 — Efficacy and Safety of Avatrombopag vs. Avatrombopag Combined With rhTPO in the Treatment of SAA · Phase 2 · unknown
NCT05772546 — Avatrombopag vs. Placebo for CIT in GI Malignancies · Phase 2 · active not recruiting
NCT05996393 — CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly · Phase 4 · completed
NCT05823376 — Avatrombopag for Platelet Recovery Post-UCBT in Patients With Bone Marrow Failure Disease · recruiting

Other recruiting trials for Thrombocytopenia

Currently open trials in the same condition.

NCT07441720 — Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) · Phase 2 · recruiting
NCT07442513 — Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT · Phase 3 · recruiting
NCT07257809 — Herombopag Treated T-DM1 Induced Platelet Reduction · Phase 2 · recruiting
NCT06676904 — Neonatal Platelet Transfusion Threshold Trial · NA · recruiting
NCT06886516 — Apixaban in Thrombocytopenia · EARLY_PHASE1 · recruiting

Other Second Affiliated Hospital of Guangzhou Medical University trials

Trials by the same sponsor.

NCT06966830 — Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus · not yet recruiting
NCT06936683 — Herpes Simplex Virus Type 1 Infection/Reactivation of Patients With Severe Pneumonia（the HSV-SP Study） · not yet recruiting
NCT07374328 — Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus · Phase 1, PHASE2 · recruiting
NCT06904183 — Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT · Phase 2 · recruiting
NCT06904196 — Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06001567 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital of Guangzhou Medical University
Last refreshed: 14 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06001567.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing